This segment focuses on the research, development, and commercialization of therapies targeting the RAS/MAPK pathway, a key driver in many cancers. Erasca's primary focus is on small molecule inhibitors. The company is developing naporafenib, an orally available pan-RAF inhibitor, for NRAS-mutated melanoma and other RAS Q16X solid tumors. ERAS-007, an oral ERK1/2 inhibitor, is being developed for non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies. ERAS-601, an oral SHP2 inhibitor, is being developed for advanced or metastatic solid tumors. ERAS-801, a central nervous system-penetrant EGFR inhibitor, is in phase 1 clinical trials for recurrent glioblastoma multiforme. The company utilizes advanced drug discovery techniques and clinical trial methodologies to evaluate the efficacy and safety of these therapies. The goal is to improve patient outcomes by providing targeted treatments for cancers driven by the RAS/MAPK pathway. Erasca has partnerships with Novartis, Katmai Pharmaceuticals, and NiKang Therapeutics to advance its pipeline. This segment is critical to Erasca's mission of erasing cancer.

This segment encompasses the planning, execution, and management of clinical trials for Erasca's drug candidates, as well as the regulatory processes required for drug approval. Erasca conducts clinical trials to evaluate the safety and efficacy of its therapies in various cancer types. The company works closely with regulatory agencies, such as the FDA, to ensure compliance with all relevant regulations and guidelines. This includes preparing and submitting regulatory filings, such as INDs and NDAs. The clinical trials segment utilizes advanced methodologies for patient recruitment, data collection, and analysis. The company's clinical trials are designed to address unmet medical needs and improve patient outcomes. The regulatory affairs component ensures that Erasca's products meet the necessary standards for market approval and patient safety. This segment is crucial for advancing Erasca's pipeline and bringing innovative cancer therapies to patients.